Yet Another Value Podcast cover image

Caligan Partners' Dave Johnson on MorphoSys' $MOR change from royalty play to traditional biotech

Yet Another Value Podcast

CHAPTER

The Dangers of HAVA

This is 18,000 patients in the USU. Like most of these rare diseases, unfortunately, it's awful. Every time I look at one of these, I'm always just like, oh my god, I'm so glad I don't have... It's terrible. The way that this disease is treated today is with a jack inhibitor called jackify from insight. So all the drugs that are being tested for mild fibrosis are all trying to do what Jack-ify does better.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner